Loading
Post-operative radiotherapy / Stage III Lung Cancer / Non Small Cell Lung Cancer · Phase 2 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 randomized controlled trial registration comparing postoperative radiotherapy to no radiotherapy in stage III NSCLC patients with residual disease after neoadjuvant chemo-immunotherapy and surgery. No results are reported in this registry record; the study is currently recruiting with planned follow-up to 60 months.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Non Small Cell Lung Cancer, Stage III Lung Cancer; age from 18 Years. Intervention: Post-operative radiotherapy. Compared with: No post-operative radiotherapy — No Intervention. n = 118. 1 site: Canada.
This is a Phase 2 randomized controlled trial registration comparing postoperative radiotherapy to no radiotherapy in stage III NSCLC patients with residual disease after neoadjuvant chemo-immunotherapy and surgery. No results are reported in this registry record; the study is currently recruiting with planned follow-up to 60 months.
Secondary endpoints (overall survival, locoregional and distant control, toxicity, quality of life) are stated but not detailed.
The source did not state who this applies to in practice.
This is an active Phase 2 randomized trial registration with no reported results; the study is recruiting and outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06878274). This is a study registration, not published results. Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM). Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 118 participants (ESTIMATED). Conditions: Non Small Cell Lung Cancer, Stage III Lung Cancer. Interventions: RADIATION: Post-operative radiotherapy. Primary outcome measures: Disease-free Survival , Defined as the time from random assignment to loco-regional or distant recurrence, or death from any cause, assessed up to 60 months.. Brief summary: This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy use, with follow-up extending up to 5 years. Statistical analysis aims to detect a 15% improvement in 2-year EFS, with a total study duration of 7 years.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.